PRNB - Principia Biopharma Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
34.32
-0.49 (-1.41%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close34.81
Open34.47
Bid0.00 x 1000
Ask0.00 x 1800
Day's Range33.64 - 35.06
52 Week Range22.00 - 42.34
Volume81,170
Avg. Volume142,523
Market Cap822.678M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.09
Earnings DateAug 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est47.50
Trade prices are not sourced from all markets
  • Should Principia Biopharma (NASDAQ:PRNB) Be Disappointed With Their 13% Profit?
    Simply Wall St.

    Should Principia Biopharma (NASDAQ:PRNB) Be Disappointed With Their 13% Profit?

    These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But you can...

  • GlobeNewswire

    Principia Biopharma Appoints Shawn Tomasello to Its Board of Directors

    “We are very excited to have Shawn join our Board as she brings an extensive track record in developing and commercializing pharmaceutical products,” said Martin Babler, president and chief executive officer at Principia Biopharma. With more than 30 years of experience in the pharmaceutical and biotech industries, Ms. Tomasello has substantial commercial and strategic experience. From 2015 to 2018, Ms. Tomasello was chief commercial officer at leading immuno-oncology cell therapy company Kite Pharma, which was acquired by Gilead Sciences.

  • GlobeNewswire

    Principia Biopharma Reports Second Quarter Financial Results

    SOUTH SAN FRANCISCO, Calif., Aug. 08, 2019 -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral.

  • GlobeNewswire

    Principia Announces Update to Ongoing Phase 2 Clinical Trial in Patients with ITP

    The ongoing open-label, dose-finding clinical trial investigating PRN1008 in patients with ITP who are refractory or relapsed with no available treatment options, was designed to test safety and activity across multiple doses – 200mg once-a-day, 400mg once-a-day, 300mg twice-a-day and 400mg twice-a-day. Principia is a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology. Principia’s proprietary Tailored Covalency® platform differentiates the company’s investigational therapies from traditional small molecules and provides the potential to deliver the potency, selectivity and safety of injectable drugs while maintaining the convenience of a pill.

  • Is Principia Biopharma Inc. (PRNB) A Good Stock To Buy?
    Insider Monkey

    Is Principia Biopharma Inc. (PRNB) A Good Stock To Buy?

    Is Principia Biopharma Inc. (NASDAQ:PRNB) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before doing days of research on it. Given their 2 and 20 payment structure, hedge funds have more incentives and resources than the average investor. The funds […]

  • GlobeNewswire

    Principia Biopharma Appoints Patrick Machado to Board of Directors

    Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced the appointment of Patrick Machado to its Board of Directors. Mr. Machado brings significant operating experience, including his time as a co-founder, chief business officer and chief financial officer of Medivation, Inc., where he provided strong leadership in the development of XTANDI® and its successful commercial launch in prostate cancer.

  • Health Care Digest: Cancer's show-and-tell meeting, a new biotech building rises and lupus patients' plea
    American City Business Journals

    Health Care Digest: Cancer's show-and-tell meeting, a new biotech building rises and lupus patients' plea

    Bay Area companies are gearing up for ASCO, HCP's Brisbane biotech building is on the rise and more in our Health Care Digest.

  • GlobeNewswire

    Principia Presents Phase 1 Data of PRN1371 in Patients with Metastatic Bladder Cancer

    The poster was presented at the AACR Bladder Cancer: Transforming the Field meeting in Denver, Colorado. This approach has the potential to enable selective and sustained inhibition of FGFR without the need to maintain high systemic exposure of the drug.

  • GlobeNewswire

    Principia Biopharma Announces First Patient Dosed in Sanofi’s Phase 2b Trial of SAR442168 in Multiple Sclerosis, Triggering $30 Million Milestone

    Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced that the first patient has been dosed in its partner Sanofi’s Phase 2b clinical trial of SAR442168 in patients with relapsing multiple sclerosis (MS), triggering a $30 million milestone payment to Principia. SAR442168, formerly known as PRN2246, is a Bruton’s tyrosine kinase (BTK) inhibitor that crosses the human blood-brain barrier and modulates immune cell function in both the periphery and in the brain, which shows promise for the potential treatment of central nervous system (CNS) diseases.

  • GlobeNewswire

    Principia Biopharma to Present at the 2019 Bank of America Merrill Lynch Health Care Conference

    Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced that management will present at the 2019 Bank of America Merrill Lynch Health Care Conference on Wednesday, May 15, 2019, at 1:00pm PT (4:00pm ET) at the Encore Hotel in Las Vegas, Nevada. Principia is a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology. PRN1008, a reversible covalent BTK inhibitor, is being evaluated in a Phase 3 clinical trial in patients with pemphigus, an orphan autoimmune disease, and in a Phase 2 clinical trial in patients with immune thrombocytopenia, a rare hematological disease.

  • GlobeNewswire

    Principia Biopharma Reports First Quarter Financial Results

    SOUTH SAN FRANCISCO, Calif., May 07, 2019 -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies.

  • Here’s What Hedge Funds Think About Principia Biopharma Inc. (PRNB)
    Insider Monkey

    Here’s What Hedge Funds Think About Principia Biopharma Inc. (PRNB)

    Is Principia Biopharma Inc. (NASDAQ:PRNB) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before doing days of research on it. Given their 2 and 20 payment structure, hedge funds have more incentives and resources than the average investor. The funds […]

  • GlobeNewswire

    Principia Biopharma Appoints Shao-Lee Lin, M.D., Ph.D. to Board of Directors

    Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced the appointment of industry veteran Shao-Lee Lin, M.D., Ph.D., a noted immunologist, rheumatologist, and allergist with significant biopharmaceutical development experience, to its Board of Directors. Dr. Lin is currently Executive Vice President, head of Research and Development and Chief Scientific Officer of Horizon Pharma plc., with past corporate experiences at AbbVie Inc., Gilead Sciences, Inc., and Amgen Inc.

  • GlobeNewswire

    Principia Biopharma Reports Fourth Quarter and Full Year 2018 Financial Results

    SOUTH SAN FRANCISCO, Calif., March 19, 2019 -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral.

  • GlobeNewswire

    Principia Biopharma Reacquires Rights to Oral Immunoproteasome Program

    Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, announced a mutual agreement with AbbVie Biotechnology Limited (AbbVie) to end their collaboration aimed at developing oral immunoproteasome inhibitors and for Principia to reacquire the rights to the program.  The two companies have agreed to conclude the collaboration effective March 2019. "AbbVie has completed an initial evaluation of Principia’s highly selective, orally bioavailable covalent inhibitors of the immunoproteasome and, after an assessment of their biologic profiles relative to AbbVie’s desired disease areas of focus, has determined that there is no longer a strategic fit,” said Martin Babler, Chief Executive Officer of Principia.

  • GlobeNewswire

    Principia Biopharma Announces Positive Data from Phase 2 Pemphigus Vulgaris Trial at 2019 American Academy of Dermatology Annual Meeting in Late-Breaking Presentation

    Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced Phase 2 clinical data from the Believe-PV study for PRN1008 as part of the Late-breaking Research: Clinical Trials program at the American Academy of Dermatology (AAD) annual meeting in Washington D.C. PRN1008 is being developed for the potential treatment of pemphigus, including pemphigus vulgaris (PV) and pemphigus foliaceus (PF). Confirming interim clinical results previously reported, the Phase 2 study reached the primary efficacy measurement of control of disease activity (CDA) on low dose corticosteroids.

  • GlobeNewswire

    Principia Biopharma Presents Phase 1 Clinical Data from CNS Penetrating BTK Inhibitor Candidate PRN2246/SAR442168 at ACTRIMS 2019

    Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, announced the presentation of Phase 1 clinical data for PRN2246, now known as SAR442168, at the American Consortium for Therapy and Research in Multiple Sclerosis (ACTRIMS) annual meeting in Dallas, Texas. PRN2246/SAR442168 is a Bruton’s tyrosine kinase (BTK) inhibitor that crosses the blood-brain barrier and modulates immune cell function in both the periphery and in the brain. PRN2246/SAR442168 is being developed for the treatment of multiple sclerosis (MS) and potentially other central nervous system (CNS) diseases under a license agreement with Sanofi, a company committed to discovering and developing new treatment options for people living with MS.

  • GlobeNewswire

    Principia Biopharma Announces the Acceptance of Data from Phase 2 Pemphigus Vulgaris Trial as a Late-Breaking Presentation at 2019 American Academy of Dermatology Meeting

    Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced that an abstract has been accepted for oral presentation at the Late-Breaking Research during the 2019 American Academy of Dermatology annual meeting in Washington, D.C. The abstract, “Final results of the Believe-PV proof of concept study of PRN1008 in pemphigus,” will be presented as part of the Late-Breaking Research: Clinical Trials on Saturday, March 2, 2019 at 2:10pm ET in Ballroom A of the Walter E. Washington Convention Center. Principia is a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology.

  • GlobeNewswire

    Principia Biopharma to Present at 8th Annual SVB Leerink Global Healthcare Conference

    Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced that management will present at the 8th Annual SVB Leerink global healthcare conference on Wednesday, February 27, 2019, at 10:00am ET at the Lotte New York Palace in New York City. Principia is a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology. PRN1008, a reversible covalent BTK inhibitor, is being evaluated in a Phase 3 clinical trial in patients with pemphigus, an orphan autoimmune disease, and in a Phase 2 clinical trial in patients with immune thrombocytopenic purpura, a rare hematological disease.

  • GlobeNewswire

    Principia Biopharma Appoints John W. Smither to Board of Directors

    Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced the appointment of industry veteran John W. Smither, Chief Financial Officer of Sienna Biopharmaceuticals, Inc., to its Board of Directors and as chairperson of its Audit Committee. “John’s expertise and counsel come at an exciting time for Principia as we pursue late-stage clinical development of our lead product candidate, PRN1008, in patients with pemphigus,” said Martin Babler, Principia’s Chief Executive Officer.

  • Principia Biopharma Inc. (NASDAQ:PRNB): Time For A Financial Health Check
    Simply Wall St.

    Principia Biopharma Inc. (NASDAQ:PRNB): Time For A Financial Health Check

    The direct benefit for Principia Biopharma Inc. (NASDAQ:PRNB), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off Read More...

  • GlobeNewswire

    Principia Biopharma Issues Statement About the Passing of Board Member Lewis J. Shuster

    Principia Biopharma Inc. (PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology today issued the following statement: “It is with great sadness that we announce that Lewis (Lew) J. Shuster, a member of the company’s board of directors, died last week due to recently diagnosed, late-stage pancreatic cancer. The entire Principia team mourns the loss of Lew and he will be dearly missed. Lew was a tremendously thoughtful and insightful board member, but more importantly, he was a kind and generous individual who brought a great deal of passion and energy to our industry and to the pursuit of our mission.

  • Health Care Digest: Where were the women in Gilead's CEO search — and more
    American City Business Journals

    Health Care Digest: Where were the women in Gilead's CEO search — and more

    Gilead's CEO search, Amyris' cannabis consideration and Principia's opportunity in this week's Health Care Digest.

  • Benzinga

    The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 29) Allakos Inc (NASDAQ: ALLK ) Emergent Biosolutions Inc ...

  • GlobeNewswire

    Principia Biopharma Reports Positive PRN1008 Phase 2 Top-Line Results and Initiates Phase 3 Pemphigus Program

    Principia Biopharma Inc. (PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced positive top-line data from the completed open-label Phase 2 trial of PRN1008 in patients with pemphigus (including both pemphigus vulgaris (PV) and pemphigus foliaceus (PF)) and the initiation of a Phase 3 trial of PRN1008 in pemphigus. The primary efficacy endpoint of the Phase 2 trial – Control of Disease Activity (CDA) within four weeks – was achieved by more than 50% of patients and PRN1008 was generally well tolerated.